Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells 2022;11(14):2249. Abstract

Aubrey BJ, Brunner AM. SOHO state of the art and next questions: Treatment of higher-risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 2022:[Online ahead of print]. Abstract

Bernard E et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence 2022;1(7). Abstract

Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study. ASH 2021;Abstract 244.

Chen JY et al. Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS). ASCO 2022;Abstract 7054.

DiNardo CD et al. Time to blur the blast boundaries. Cancer 2022;128(8):1568-70. Abstract

Estey EH et al. Distinguishing AML from MDS: A fixed blast percentage may no longer be optimal. Blood 2021;139(3):323-32. Abstract

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.

Garcia-Manero G et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study. ASCO 2021;Abstract TPS7055.

Garcia-Manero G et al. Oral cedazuridine/decitabine for MDS and CMML: A phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 2020;136(6):674-83. Abstract

Garcia-Manero G et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up of the ASCERTAIN study. ASH 2021;Abstract 66.

Garcia-Manero G et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2021;39(13):1426-36. Abstract

Komrokji R et al. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? Leuk Lymphoma 2021;62(11):2762-7. Abstract

Sallman DA et al. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy. ASCO 2022;Abstract 7053.

Sallman DA et al. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results. ASCO 2022;Abstract 7017.

Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacytidine in MDS and AML patients: Phase 1b results. ASCO 2020;Abstract 7507.

Sekeres MA et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% marrow blasts: The randomized phase 3 PANTHER trial (NCT03268954). ASH 2021;Abstract 242.

Upton R et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A 2021;118(29):e2026849118. Abstract

Venugopal S et al. A phase I/II study of venetoclax in combination with ASTX727 (cedazuridine/decitabine) in treatment‐naïve high‐risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). ASH 2021;Abstract 245.

Volpe VO et al. Myelodysplastic syndromes: A new decade. Clin Lymphoma Myeloma Leuk 2022;22(1):1-16. Abstract

Zeidan AM et al. Venetoclax and azacitidine in the treatment of patients with relapsed/refractory myelodysplastic syndrome. ASH 2021;Abstract 537.